ReviewCurrent gastroenterology reports2023
Current Status of Living Donor Liver Transplantation: Impact, Advantages, and Challenges.
Review in Current gastroenterology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Living donor outcomes in an emerging living donor liver transplantation program: A single-center experience from Malaysia.World journal of transplantation · 2026Article
- Impact of bile duct number and anastomosis technique on postoperative morbidity and mortality in living and deceased donor liver transplantation.Turkish journal of surgery · 2026Article
- Living Donor Training During ASTS Fellowship: Disparities in Autonomy Between Kidney and Liver Donation. A National Survey.Clinical transplantation · 2026Article
- Prediction of graft loss in living donor liver transplantation during the early postoperative period.PLoS computational biology · 2025Article
- Hepatocellular Carcinoma Transplant Criteria Show Poor Negative Predictive Value: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2025Review
- Auxiliary liver transplantation using otherwise-discarded liver allograft combined with associating liver partition and portal vein ligation for staged hepatectomy for unresectable colorectal liver metastases.Hepatobiliary surgery and nutrition · 2025Article
- High-volume living donor liver transplantation (LDLT): what the data tells us.Hepatobiliary surgery and nutrition · 2025Article
- Transplant Without Borders: Clinical Outcomes and Challenges in Transborder Living Donor Pediatric Liver Transplantation in Jordan.Therapeutics and clinical risk management · 2025Article
- Mortality and associated factors among patients who underwent liver transplantation in South Korea from 2017 to 2021: a retrospective observational study.Annals of surgical treatment and research · 2024Article
- Clinical Factors Affecting the Rate of Liver Regeneration in Living Donors after Right Hepatectomy.Journal of personalized medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of this reviewThis review provides an overview of the current status of Living Donor Liver Transplant (LDLT). It discusses the impact of LDLT on waitlist and post-transplantation outcomes, highlighting the technical challenges and unique advantages of LDLT. RECENT
findingsRecent findings show that LDLT offers several theoretical advantages over deceased donor liver transplant, including shorter wait times, better graft quality, and improved post-transplant outcomes. Non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC) are emerging as the leading indications for adult LDLT in the US. LDLT demonstrates comparable or better overall survival rates and organ-specific outcomes compared to deceased donor transplants. However, challenges exist, including donor and recipient risks such as biliary complications and small-for-size syndrome. Ongoing research focuses on refining surgical techniques, exploring minimally invasive approaches, utilizing predetermined donors to modulate the recipient's immune system, and ensuring ethical practices. LDLT is a valuable solution for patients with end-stage liver failure or disorders requiring transplantation. It offers advantages such as shorter wait times as well as improved waitlist and post-transplant outcomes. Continued research and advancements in LDLT will benefit patients in need of liver transplantation.
Indexed as
Identifiers
37603108What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.